NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

肺動脈高血壓 (PAH) 治療藥的全球市場 (2021-2027年):市場預測 (各醫藥品分類、給藥途徑)、COVID-19的影響、地區性展望、用途的潛在性、價格趨勢、市場佔有率

Pulmonary Arterial Hypertension Market Size By Drug Class, By Route of Administration, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

出版商 Global Market Insights Inc. 商品編碼 1024859
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
肺動脈高血壓 (PAH) 治療藥的全球市場 (2021-2027年):市場預測 (各醫藥品分類、給藥途徑)、COVID-19的影響、地區性展望、用途的潛在性、價格趨勢、市場佔有率 Pulmonary Arterial Hypertension Market Size By Drug Class, By Route of Administration, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027
出版日期: 2021年08月20日內容資訊: 英文 120 Pages
簡介

心血管疾病全球增加和老年人口增加,肺動脈高血壓 (PAH)的市場預計到2027年顯示大幅度的成長。

各醫藥品分類中,血管擴張藥的部門2020年顯示相當的市場佔有率,表現超過13億6500萬美元的規模。預計使用血管擴張劑改善重病患者的存活率促進在預測期間內的成長。還有各給藥途徑中,靜脈注射的部門2020年顯示很大的佔有率,到2027年終成長超過15億5500萬美元的規模。靜脈注射由於有速效性,可有效藥物輸送,預計成長。

本報告提供全球肺動脈高血壓 (PAH) 治療藥的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,市場規模的變化、預測,醫藥品分類、給藥途徑、地區/主要國家等各種區分的明細,競爭環境,市場佔有率,主要企業簡介等彙整資訊。

第1章 調查手法

第2章 摘要整理

第3章 產業考察

  • 產業的分類
  • 產業形勢
  • 產業的影響因素
    • 成長要素
    • 潛在的風險&課題
  • 成長可能性
  • COVID-19:影響分析
  • 波特分析
  • 競爭情形
  • PESTEL分析

第4章 市場分析、預測:各醫藥品分類

  • 前列腺環素、前列腺環素類似體
  • 可溶性鳥苷酸環化酶(SGC)刺激劑
  • 內皮素受體拮抗劑(ERA)
  • 磷酸二酯酶5(PDE-5)
  • 血管擴張藥
  • 其他

第5章 市場分析、預測:各給藥途徑

  • 口服
  • 靜脈內
  • 吸入

第6章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第7章 企業簡介

  • 競爭儀表板
  • Bayer AG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Pfizer, Inc.
  • United Therapeutics Corporation
目錄
Product Code: 1939

The pulmonary arterial hypertension market is projected to grow significantly by 2027 owing to rising incidences of cardiovascular diseases across the globe. In addition, the expanding geriatric population is likely to further drive market growth through the forecast period.

Many cardiovascular diseases, including pulmonary arterial hypertension (PAH), have come into focus in view of the ongoing COVID-19 pandemic. The novel coronavirus has been found to cause or escalate existing heart ailments in some patients, particularly in those above the age of 65 years.

Notably, many lifestyle habits, such as smoking, drinking, and consuming packaged foods, among others, are known to contribute to pulmonary arterial hypertension. Recently, growing occurrences of PAH have become a cause for concern among governments worldwide. Subsequently, increasing research efforts towards the development of improved drugs supported by favorable government initiatives have augmented industry expansion in leading regions.

Moreover, surging focus on the development of effective therapies has been favorable for the global product landscape, thereby enhancing market dynamics. For instance, in August 2021, the Food and Drug Administration (FDA) approved the Uptravi (selexipag) injection for intravenous (IV) use in the treatment of pulmonary arterial hypertension (PAH, WHO Group I). The injection has been formulated to delay disease progression as well as lower the risk of hospitalization for PAH with WHO Functional Class II-III in adults who are temporarily unable to take oral therapy. Thus, increasing availability of targeted therapeutics has been favorable for industry growth.

The pulmonary arterial hypertension market has been categorized based on route of administration, drug class, and region. With respect to drug class, the market has further been bifurcated into vasodilators, endothelin receptor antagonist (ERA), prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), soluble guanylate cyclase (SGC) stimulators, and others.

The vasodilators drug class segment held a considerable market share in 2020 and was valued at over USD 1,365 million. Increased survival chances in critical patients with the use of vasodilators is set to propel segmental growth through the forecast period.

Based on route of administration, the market has been segregated into inhalation, oral, and intravenous. The intravenous route of administration segment held a sizeable market share in 2020 and is expected to grow at a solid pace to attain a revenue of more than USD 1,555 million by the end of 2027. Fast-acting and effective form of drug delivery provided by intravenous therapy is foreseen to facilitate segmental expansion over the study timeline.

From the regional point of view, the Middle East & Africa pulmonary arterial hypertension market was valued at around USD 124 million in 2020 and is anticipated to amass profitable gains by the end of 2027. Rising prevalence of pulmonary arterial hypertension disorder across MEA is slated to foster regional market growth through the estimated timeframe.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definition
  • 1.2 Base estimates & working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Pulmonary arterial hypertension industry 360 degree synopsis, 2016 - 2027
    • 2.1.1 Business trends
    • 2.1.2 Drug class trends
    • 2.1.3 Route of administration trends
    • 2.1.4 Regional trends

Chapter 3 Pulmonary Arterial Hypertension Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027 (USD Million)
  • 3.3 Industry impact factors
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increase in prevalence of pulmonary arterial hypertension
      • 3.3.1.2 Strong product pipeline
      • 3.3.1.3 Growing government initiatives
      • 3.3.1.4 Rising global geriatric population
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Patent expiration
      • 3.3.2.2 Side effects associated with the drugs
  • 3.4 Growth potential analysis
    • 3.4.1 By drug class
    • 3.4.2 By route of administration
  • 3.5 COVID-19 impact analysis
  • 3.6 Porter's analysis
  • 3.7 Competitive landscape, 2020
    • 3.7.1 Company matrix analysis, 2020
  • 3.8 PESTEL analysis

Chapter 4 Pulmonary Arterial Hypertension Market, By Drug Class

  • 4.1 Key segment trends
  • 4.2 Prostacyclin and prostacyclin analogs
    • 4.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.3 Soluble guanylate cyclase (SGC) stimulators
    • 4.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.4 Endothelin receptor antagonist (ERA)
    • 4.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.5 Phosphodiesterase 5 (PDE-5)
    • 4.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.6 Vasodilators
    • 4.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.7 Others
    • 4.7.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 5 Pulmonary Arterial Hypertension Market, By Drug Class

  • 5.1 Key segment trends
  • 5.2 Oral
    • 5.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.3 Intravenous
    • 5.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.4 Inhalation
    • 5.4.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 6 Pulmonary Arterial Hypertension Market, By Region

  • 6.1 Key regional trends
  • 6.2 North America
    • 6.2.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.2.2 Market size, by drug class, 2016 - 2027 (USD Million)
    • 6.2.3 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.2.4 U.S.
      • 6.2.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.2.4.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.2.5 Canada
      • 6.2.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.2.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
  • 6.3 Europe
    • 6.3.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.3.2 Market size, by drug class, 2016 - 2027 (USD Million)
    • 6.3.3 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.3.4 Germany
      • 6.3.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.3.4.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.3.5 UK
      • 6.3.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.3.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.3.6 France
      • 6.3.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.3.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.3.7 Spain
      • 6.3.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.3.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.3.8 Italy
      • 6.3.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.3.8.2 Market size, by route of administration, 2016 - 2027 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.4.2 Market size, by drug class, 2016 - 2027 (USD Million)
    • 6.4.3 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.4.4 Japan
      • 6.4.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.4.4.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.4.5 China
      • 6.4.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.4.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.4.6 India
      • 6.4.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.4.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.4.7 Australia
      • 6.4.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.4.7.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.4.8 South Korea
      • 6.4.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.4.8.2 Market size, by route of administration, 2016 - 2027 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.5.2 Market size, by drug class, 2016 - 2027 (USD Million)
    • 6.5.3 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.5.4 Brazil
      • 6.5.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.5.4.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.5.5 Mexico
      • 6.5.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.5.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.5.6 Argentina
      • 6.5.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.5.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)
  • 6.6 Middle East and Africa
    • 6.6.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.6.2 Market size, by drug class, 2016 - 2027 (USD Million)
    • 6.6.3 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.6.4 South Africa
      • 6.6.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.6.4.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.6.5 Saudi Arabia
      • 6.6.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.6.5.2 Market size, by route of administration, 2016 - 2027 (USD Million)
    • 6.6.6 UAE
      • 6.6.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
      • 6.6.6.2 Market size, by route of administration, 2016 - 2027 (USD Million)

Chapter 7 Company Profiles

  • 7.1 Competitive dashboard, 2020
  • 7.2 Bayer AG
    • 7.2.1 Business overview
    • 7.2.2 Financial data
    • 7.2.3 Product landscape
    • 7.2.4 Strategic outlook
    • 7.2.5 SWOT analysis
  • 7.3 Eli Lilly and Company
    • 7.3.1 Business overview
    • 7.3.2 Financial data
    • 7.3.3 Product landscape
    • 7.3.4 Strategic outlook
    • 7.3.5 SWOT analysis
  • 7.4 Gilead Sciences, Inc.
    • 7.4.1 Business overview
    • 7.4.2 Financial data
    • 7.4.3 Product landscape
    • 7.4.4 Strategic outlook
    • 7.4.5 SWOT analysis
  • 7.5 GlaxoSmithKline plc.
    • 7.5.1 Business overview
    • 7.5.2 Financial data
    • 7.5.3 Product landscape
    • 7.5.4 Strategic outlook
    • 7.5.5 SWOT analysis
  • 7.6 Johnson & Johnson
    • 7.6.1 Business overview
    • 7.6.2 Financial data
    • 7.6.3 Product landscape
    • 7.6.4 Strategic outlook
    • 7.6.5 SWOT analysis
  • 7.7 Pfizer, Inc.
    • 7.7.1 Business overview
    • 7.7.2 Financial data
    • 7.7.3 Product landscape
    • 7.7.4 Strategic outlook
    • 7.7.5 SWOT analysis
  • 7.8 United Therapeutics Corporation
    • 7.8.1 Business overview
    • 7.8.2 Financial data
    • 7.8.3 Product landscape
    • 7.8.4 Strategic outlook
    • 7.8.5 SWOT analysis

Data Tables

  • TABLE 1. Pulmonary arterial hypertension industry 360 degree synopsis, 2016-2027
  • TABLE 2. Global pulmonary arterial hypertension market, 2016 - 2020 (USD Million)
  • TABLE 3. Global pulmonary arterial hypertension market, 2021 - 2027 (USD Million)
  • TABLE 4. Global pulmonary arterial hypertension market, by drug class, 2016 - 2020 (USD Million)
  • TABLE 5. Global pulmonary arterial hypertension market, by drug class, 2021 - 2027 (USD Million)
  • TABLE 6. Global pulmonary arterial hypertension market, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 7. Global pulmonary arterial hypertension market, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 8. Global pulmonary arterial hypertension market, by region, 2016 - 2020 (USD Million)
  • TABLE 9. Global pulmonary arterial hypertension market, by region, 2021 - 2027 (USD Million)
  • TABLE 10. Industry impact forces
  • TABLE 11. Prostacyclin and prostacyclin analogs market size, by region, 2016 - 2020 (USD Million)
  • TABLE 12. Prostacyclin and prostacyclin analogs market size, by region, 2021 - 2027 (USD Million)
  • TABLE 13. Soluble guanylate cyclase (SGC) stimulators market size, by region, 2016 - 2020 (USD Million)
  • TABLE 14. Soluble guanylate cyclase (SGC) stimulators market size, by region, 2021 - 2027 (USD Million)
  • TABLE 15. Endothelin receptor antagonist (ERA) market size, by region, 2016 - 2020 (USD Million)
  • TABLE 16. Endothelin receptor antagonist (ERA) market size, by region, 2021 - 2027 (USD Million)
  • TABLE 17. Phosphodiesterase 5 (PDE-5) market size, by region, 2016 - 2020 (USD Million)
  • TABLE 18. Phosphodiesterase 5 (PDE-5) market size, by region, 2021 - 2027 (USD Million)
  • TABLE 19. Vasodilators market size, by region, 2016 - 2020 (USD Million)
  • TABLE 20. Vasodilators market size, by region, 2021 - 2027 (USD Million)
  • TABLE 21. Others market size, by region, 2016 - 2020 (USD Million)
  • TABLE 22. Others market size, by region, 2021 - 2027 (USD Million)
  • TABLE 23. Oral market size, by region, 2016 - 2020 (USD Million)
  • TABLE 24. Oral market size, by region, 2021 - 2027 (USD Million)
  • TABLE 25. Intravenous market size, by region, 2016 - 2020 (USD Million)
  • TABLE 26. Intravenous market size, by region, 2021 - 2027 (USD Million)
  • TABLE 27. Inhalation market size, by region, 2016 - 2020 (USD Million)
  • TABLE 28. Inhalation market size, by region, 2021 - 2027 (USD Million)
  • TABLE 29. North America pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)
  • TABLE 30. North America pulmonary arterial hypertension market size, by country, 2021 - 2027 (USD Million)
  • TABLE 31. North America pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 32. North America pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 33. North America pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 34. North America pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 35. U.S. pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 36. U.S. pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 37. U.S. pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 38. U.S. pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 39. Canada pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 40. Canada pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 41. Canada pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 42. Canada pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 43. Europe pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)
  • TABLE 44. Europe pulmonary arterial hypertension market size, by country, 2021 - 2027 (USD Million)
  • TABLE 45. Europe pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 46. Europe pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 47. Europe pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 48. Europe pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 49. Germany pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 50. Germany pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 51. Germany pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 52. Germany pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 53. UK pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 54. UK pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 55. UK pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 56. UK pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 57. France pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 58. France pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 59. France pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 60. France pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 61. Spain pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 62. Spain pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 63. Spain pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 64. Spain pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 65. Italy pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 66. Italy pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 67. Italy pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 68. Italy pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 69. Asia Pacific pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)
  • TABLE 70. Asia Pacific pulmonary arterial hypertension market size, by country, 2021 - 2027 (USD Million)
  • TABLE 71. Asia Pacific pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 72. Asia Pacific pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 73. Asia Pacific pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 74. Asia Pacific pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 75. Japan pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 76. Japan pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 77. Japan pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 78. Japan pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 79. China pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 80. China pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 81. China pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 82. China pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 83. India pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 84. India pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 85. India pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 86. India pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 87. Australia pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 88. Australia pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 89. Australia pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 90. Australia pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 91. South Korea pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 92. South Korea pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 93. South Korea pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 94. South Korea pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 95. Latin America pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)
  • TABLE 96. Latin America pulmonary arterial hypertension market size, by country, 2021 - 2027 (USD Million)
  • TABLE 97. Latin America pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 98. Latin America pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 99. Latin America pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 100. Latin America pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 101. Brazil pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 102. Brazil pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 103. Brazil pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 104. Brazil pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 105. Mexico pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 106. Mexico pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 107. Mexico pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 108. Mexico pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 109. Argentina pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 110. Argentina pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 111. Argentina pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 112. Argentina pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 113. MEA pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)
  • TABLE 114. MEA pulmonary arterial hypertension market size, by country, 2021 - 2027 (USD Million)
  • TABLE 115. MEA pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 116. MEA pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 117. MEA pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 118. MEA pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 119. South Africa pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 120. South Africa pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 121. South Africa pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 122. South Africa pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 123. Saudi Arabia pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 124. Saudi Arabia pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 125. Saudi Arabia pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 126. Saudi Arabia pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)
  • TABLE 127. UAE pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)
  • TABLE 128. UAE pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)
  • TABLE 129. UAE pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)
  • TABLE 130. UAE pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)

Charts & Figures

  • FIG. 1 Market estimation and forecast methodology
  • FIG. 2 Top-down approach
  • FIG. 3 Industry segmentation
  • FIG. 4 Global pulmonary arterial hypertension market size, 2016 - 2027 (USD Million)
  • FIG. 5 Growth potential analysis, by drug class
  • FIG. 6 Growth potential analysis, by route of administration
  • FIG. 7 Porter's analysis
  • FIG. 8 Competitive matrix analysis
  • FIG. 9 PESTEL analysis
  • FIG. 10 Key segment trends, by drug class
  • FIG. 11 Key segment trends, by route of administration
  • FIG. 12 Key regional trends
  • FIG. 13 Competitive dashboard, 2020